Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383043 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL6880352 | 0.84 | MT-CO2 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL16236160 | 0.83 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL20163123 | 0.80 | TRPV1 (0.40) | CYP3A4CYP2C9CYP2C19PAX8 | |
| SCHEMBL978403 | 0.79 | GPR119 (0.43) | PAX8 | |
| SCHEMBL29899039 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2GSK3BMEN1KMT2A | |
| SCHEMBL16236159 | 0.78 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL979761 | 0.78 | MAPT (0.49) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL4361288 | 0.77 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP3A4 | |
| SCHEMBL30875817 | 0.77 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-07 | — | — | US | claimed |
| EP-1172356-A1 | Process for producing N-acylnitroaniline derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-16 | — | — | EP | claimed |
| CN-116348114-A | Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof | 高丽大学校产学协力团 | 2023-06-27 | — | — | CN | disclosed |
| US-9266822-B2 | Solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8729130-B2 | Methods of using novel solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003413-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| JP-2002088048-A | METHOD FOR PRODUCING N-T-BUTOXYCARBONYLNITROANLINE DERIVATIVE | SUMITOMO CHEM CO LTD | 2002-03-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | ALDH1A1 3839/4885SMN1; SMN2 2469/4885GSK3B 917/4885 |
| US-20020016506-A1 | Process for producing N-acylnitroaniline derivative | NAAA, NAT1, ACOT7 | ALDH1A1 824/4885SMN1; SMN2 1508/4885GSK3B 4095/4885 |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | ALDH1A1 3839/4885SMN1; SMN2 2469/4885GSK3B 917/4885 |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, FAM162A, ACAT2 | ALDH1A1 3973/4885SMN1; SMN2 2598/4885GSK3B 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.